

# Contents

Foreword . . . . .	v
<i>Karen Antman</i>	
Foreword to the Second Edition . . . . .	vii
<i>Derek Crowther</i>	
Foreword to the First Edition . . . . .	ix
<i>E. Donall Thomas</i>	
Foreword to the First Edition . . . . .	xi
<i>Sir David J. Weatherall</i>	
Preface. . . . .	xiii
Contributors . . . . .	xvii
Color Plates. . . . .	xix
Chapter 1 Selecting the Right Targets for Cancer Therapy. . . . .	1
<i>Miguel H. Bronchud</i>	
Chapter 2 Clinical Importance of Prognostic Factors: <i>Moving from Scientifically Interesting to Clinically Useful</i> . . . . .	27
<i>N. Lynn Henry and Daniel F. Hayes</i>	
Chapter 3 Genetic Markers in Sporadic Tumors. . . . .	43
<i>Elena Tamborini, Federica Perrone, Milo Frattini, Tiziana Negri, Antonella Aiello, Annunziata Gloghini, Antonino Carbone, Silvana Pilotti, and Marco A. Pierotti</i>	
Chapter 4 Genetic Markers in Breast Tumors with Hereditary Predisposition. . . . .	85
<i>Tatyana A. Grushko and Olufunmilayo I. Olopade</i>	
Chapter 5 Circulating Tumor Markers. . . . .	107
<i>Alan Horwich and Gill Ross</i>	
Chapter 6 Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways . . . . .	117
<i>Steven Pelech and Hong Zhang</i>	
Chapter 7 Gene Expression Arrays for Pathway Analysis in Cancer Research . . . . .	135
<i>Xiang Sean Yu, Raymond K. Blanchard, Yexun Wang, and Min You</i>	
Chapter 8 Signaling Pathways in Cancer . . . . .	153
<i>Daniel Kalderon</i>	
Chapter 9 Estrogen Receptor Pathways and Breast Cancer . . . . .	189
<i>Jing Peng and V. Craig Jordan</i>	

Chapter 10	Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics . . . . .	207
	<i>Marcos Malumbres</i>	
Chapter 11	Angiogenesis Switch Pathways . . . . .	239
	<i>Jaume Piulats and Francesc Mitjans</i>	
Chapter 12	Apoptosis Pathways and New Anticancer Agents . . . . .	257
	<i>Frank A.E. Kruyt, Jose A. Rodriguez, and Giuseppe Giaccone</i>	
Chapter 13	Genomic Instability, DNA Repair Pathways and Cancer . . . . .	269
	<i>Gabriel Capellá, Josep Balart, and Miguel Angel Peinado</i>	
Chapter 14	Epigenomics and Cancer . . . . .	281
	<i>Isabel López de Silanes and Manel Esteller</i>	
Chapter 15	Harnessing the Power of Immunity to Battle Cancer: <i>Much Ado about Nothing or All's Well That Ends Well?</i> . . . . .	293
	<i>Angelo A. Cardoso</i>	
Chapter 16	Aurora Kinases: A New Target for Anticancer Drug Development. . . . .	307
	<i>Teresa Macarulla, Francisco Javier Ramos, and Josep Tabernero</i>	
Chapter 17	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways . . . . .	317
	<i>Alison H.M. Reid, Richard Baird, and Paul Workman</i>	
Chapter 18	Suicide Gene Therapy . . . . .	367
	<i>Silke Schepelmann, Ion Niculescu-Duvaz, and Caroline J. Springer</i>	
Chapter 19	Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs . . . . .	383
	<i>Rosario García-Campelo, Miquel Tarón, Itziar De Aguirre, Pedro Méndez, and Rafael Rosell</i>	
Chapter 20	A Personal Account of the Chemoprevention of Breast Cancer: <i>Possible or Not Possible?</i> . . . . .	391
	<i>V. Craig Jordan</i>	
	Abbreviations . . . . .	399
	Trade Names/Generic Names . . . . .	403
	Index . . . . .	405

Principles of Molecular Oncology

Bronchud, M.H.; Foote, M.; Giaccone, G.; Olopade, O.I.;  
Workman, P. (Eds.)

2008, XX, 420 p. 85 illus., 21 illus. in color.,

ISBN: 978-1-59745-470-4

A product of Humana Press